

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by Sisram Medical Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce the establishment of a new direct office in Thailand. The new direct office will start with the injectables business, as the Company has obtained approval from the Thailand Food and Drug Administration to provide Profhilo®, an injectable product exclusively distributed by the Company, and looks forward to registering further products to improve customer experience and optionality.

The Company is always proactively seeking suitable strategic markets to set up direct operations, so as to enhance customer interactions, strengthen relationships with customers and end users, and augment brand awareness. Thailand is a growing and dynamic market in the global aesthetics field and is a key rising economy in Southeast Asia.

The Company is therefore confident that its expansion into Thailand offers exciting long-term growth opportunities for its brand and business in the region and globally, by promoting the Company’s full portfolio as a wellness ecosystem and showcasing its new and innovative products. This will maximise returns to shareholders and benefit the Company and its shareholders as a whole.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board  
**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
**Yi LIU**  
*Chairman*

Hong Kong, September 30, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* for identification purpose only